Summit Therapeutics Inc. SMMT
We take great care to ensure that the data presented and summarized in this overview for Summit Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SMMT
View all-
Baker Bros. Advisors LP New York, NY33.7MShares$620 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$160 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$145 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$73.9 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$71.8 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.93MShares$54 Million0.0% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V82.16MShares$39.8 Million0.05% of portfolio
-
Ubs Group Ag2.09MShares$38.5 Million0.01% of portfolio
-
Norges Bank Oslo, Q81.39MShares$25.6 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA1.29MShares$23.8 Million0.0% of portfolio
Latest Institutional Activity in SMMT
Top Purchases
Top Sells
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Insider Transactions at SMMT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2025
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.0%
|
$90,000
$18.07 P/Share
|
|
Sep 11
2025
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.0%
|
$90,000
$18.07 P/Share
|
|
Sep 10
2025
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
333,394
+0.06%
|
$5,667,698
$17.68 P/Share
|
|
Sep 10
2025
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
333,394
+0.06%
|
$5,667,698
$17.68 P/Share
|
|
May 30
2025
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
74,545
+0.01%
|
$149,090
$2.64 P/Share
|
|
May 30
2025
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
74,545
+0.01%
|
$149,090
$2.64 P/Share
|
|
Apr 08
2025
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
3,985,055
+0.71%
|
$3,985,055
$1.58 P/Share
|
|
Apr 08
2025
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
3,985,055
+0.71%
|
$3,985,055
$1.58 P/Share
|
|
Oct 03
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
315,681
+3.0%
|
$315,681
$1.58 P/Share
|
|
Sep 11
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
44,052
+0.18%
|
$969,144
$22.7 P/Share
|
|
Sep 11
2024
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,325,991
+0.6%
|
$73,171,802
$22.7 P/Share
|
|
Sep 11
2024
|
Jeff Huber Director |
BUY
Grant, award, or other acquisition
|
Indirect |
44,052
+50.0%
|
$969,144
$22.7 P/Share
|
|
Sep 11
2024
|
Bhaskar Anand Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,026
+14.35%
|
$484,572
$22.7 P/Share
|
|
Sep 11
2024
|
Manmeet Singh Soni COO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
44,052
+1.44%
|
$969,144
$22.7 P/Share
|
|
Mar 27
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
54,321
+14.35%
|
$162,963
$3.72 P/Share
|
|
Mar 27
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
26,000
+4.75%
|
$78,000
$3.72 P/Share
|
|
Mar 26
2024
|
Ankur Dhingra Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
100,000
+21.98%
|
$300,000
$3.75 P/Share
|
|
Mar 26
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
30,000
+50.0%
|
$90,000
$3.75 P/Share
|
|
Dec 13
2023
|
Ankur Dhingra Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
20,400
+3.73%
|
$40,800
$2.16 P/Share
|
|
Dec 12
2023
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+1.0%
|
$10,000
$2.07 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 149K shares |
|---|---|
| Open market or private purchase | 677K shares |
| Exercise of in-the-money or at-the-money derivatives securities | 8.29M shares |